Vicore Pharma AB (VCRE) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Vicore Pharma AB is the larger company by market cap ($252.9 million vs $243.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VCRE | VNDA |
|---|---|---|
| Share price | $8.98 | $4.03 |
| Market cap | $252.92M | $243.66M |
| 1-day change | -1.21% | -4.95% |
| YTD return | — | -54.31% |
| 1-year return | — | -23.53% |
| 5-year return | — | -77.98% |
| Forward P/E | — | 20.15 |
| EPS (TTM) | $-2.04 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $216.10M |
| Revenue growth (YoY) | — | +8.72% |
| Net income (latest FY) | — | $-220.47M |
| Gross margin | — | 93.96% |
| Operating margin | — | -69.95% |
| Net margin | — | -102.02% |
| 52-week high | $17.80 | $9.94 |
| 52-week low | $7.88 | $4.00 |
| Distance from 52-week high | -49.55% | -59.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +223.83% | +191.56% |
| Average volume | 17.84K | 968.38K |
| Shares outstanding | 28.16M | 60.46M |
| Employees | 46 | 533 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
VCRE vs VNDA FAQ
Which is bigger, Vicore Pharma AB or Vanda Pharmaceuticals?
Vicore Pharma AB (VCRE) is larger, with a market capitalization of $252.92M compared with $243.66M for Vanda Pharmaceuticals (VNDA).
Are Vicore Pharma AB and Vanda Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.